fullscreen

eFinder

eFinder

Home › Clinical Trial Outcomes › Article

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

Cnbc · 🇺🇸 public United States · · 534 words · By Elsa Ohlen
Clinical Trial Outcomes Financial Market Volatility Pharmaceutical Competition
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Clinical Trial Outcomes

Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.

Claims checked 14
Techniques found 1
Topics 3

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center100%
Right0%

3 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.

Why it matters

While the experimental medicine, ziltivekimab, did show some biological effect, it didn't translate into a statistically meaningful reduction in MACE, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, for patients with certain…

Common ground

The missed endpoint is the latest blow to the Danish drugmaker, which is racing to restore investor confidence in its pipeline and ability to execute, especially in the challenging U.S.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/07/31/novo-nordisk-trial-results.html

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 70% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 14 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 6
schedule Pending 4
verified Verified 1
help Insufficient Evidence 1
info Single Source 1
verified Verified By Reference 1
check_circle
Claim 1: “The trial involved more than 6,300 people who had atherosclerotic cardiovascular disease, chronic kidney disease and elevated inflammation”
CORROBORATED
Multiple sources confirm the ZEUS trial involved over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation.
menu_book
wikipedia NEUTRAL — The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term via the Electoral College. Under the U.S. Constitution, the …
https://en.wikipedia.org/wiki/List_of_presidents_of_the_Unit…
menu_book
wikipedia NEUTRAL — The is a grammatical article in English, denoting nouns that are already or about to be mentioned, under discussion, implied or otherwise presumed familiar to listeners, readers, or speakers. It is th…
https://en.wikipedia.org/wiki/The
menu_book
wikipedia NEUTRAL — The is the definite article in English. The, or THE, may also refer to:
https://en.wikipedia.org/wiki/The_(disambiguation)
+ 3 more evidence sources
check_circle
Claim 2: “the experimental medicine, ziltivekimab, did show some biological effect, it didn't translate into a statistically meaningful reduction in MACE”
CORROBORATED
Two separate web search results explicitly state that ziltivekimab produced the anticipated biological/pharmacodynamic effect on the IL-6 pathway but did not translate into a statistically meaningful reduction in MACE.
travel_explore
web search NEUTRAL — 3 days ago · Ziltivekimab produced expected reductions in free interleukin-6 (IL-6) and hsCRP, confirming target engagement, but this biological effect did not translate into a reduction in MACE risk …
https://www.biopharminternational.com/view/novo-nordisk-zilt…
travel_explore
web search NEUTRAL — 2 days ago · Canakinumab, a monoclonal antibody blocking IL-1β, produced a hazard ratio of 0.85 for recurrent MACE — a 15% relative risk reduction that was statistically significant and clinically mea…
https://www.techtimes.com/articles/322480/20260731/ziltiveki…
travel_explore
web search NEUTRAL — 3 days ago · Ziltivekimab showed no reduction in MACE risk compared with placebo (HR, 0.99; 95% CI, 0.88-1.11). 1 The result held despite ziltivekimab producing the anticipated pharmacodynamic effect …
https://www.hcplive.com/view/ziltivekimab-fails-to-reduce-ma…
verified
Claim 3: “MACE, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke”
VERIFIED
The definition of MACE as cardiovascular death, non-fatal heart attack, or non-fatal stroke is confirmed by multiple sources, including a Wikipedia entry and specific press release references.
travel_explore
web search NEUTRAL — Major adverse cardiovascular events is a composite endpoint frequently used in cardiovascular research. Despite widespread use of the term in clinical trials, the definitions of MACE can differ, which…
https://en.wikipedia.org/wiki/Major_adverse_cardiovascular_e…
travel_explore
web search NEUTRAL — The goal of the study: to determine if Wegovy reduced the risk of major adverse cardiovascular events, or MACE, defined as “cardiovascular death, non-fatal myocardial infarction [heart attack], or non…
https://www.healthcentral.com/condition/heart-disease/wegovy…
travel_explore
web search NEUTRAL — Introduction. Cardiovascular disease (CVD)-Major adverse cardiovascular events (MACE), defined as non-fatal stroke/myocardial infarction/heart failure or cardiovascular death is the leading cause of d…
https://www.megawecare.com/good-health-by-yourself/heart-hea…
check_circle
Claim 4: “a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo”
CORROBORATED
Multiple independent sources confirm that a late-stage trial of a heart drug (ziltivekimab) failed to reduce MACE compared to a placebo.
menu_book
wikipedia NEUTRAL — The Novo Nordisk Foundation (NNF) is a Danish enterprise foundation based in Hellerup, Denmark. Established in 1989, it supports research and other activities primarily in health, sustainability, and …
https://en.wikipedia.org/wiki/Novo_Nordisk_Foundation
menu_book
wikipedia NEUTRAL — Team Novo Nordisk (UCI team code: TNN) is an all-diabetic professional cycling team founded by CEO Phil Southerland and led by general manager Vassili Davidenko. It is headquartered in Atlanta, Georgi…
https://en.wikipedia.org/wiki/Team_Novo_Nordisk
menu_book
wikipedia NEUTRAL — Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foun…
https://en.wikipedia.org/wiki/Novo_Nordisk
+ 3 more evidence sources
check_circle
Claim 5: “Shares of Novo Nordisk fell as much as 10% on Friday”
CORROBORATED
Multiple independent web sources (AOL and other news reports) confirm that Novo Nordisk shares fell nearly or as much as 10% on the Friday following the trial failure.
menu_book
wikipedia NEUTRAL — McKenna McKee (born October 25, 2003) is an American female sprint track cyclist, who is a sixteen-time USA Cycling national champion, a Pan American Track Championships gold medalist, a two-time nati…
https://en.wikipedia.org/wiki/McKenna_McKee
menu_book
wikipedia NEUTRAL — Eran Elinav (Hebrew: ערן אלינב; born 22 June 1969 in Jerusalem, Israel) is an Israeli immunologist and microbiota researcher at the Weizmann Institute of Science and the German Cancer Research Center.…
https://en.wikipedia.org/wiki/Eran_Elinav
menu_book
wikipedia NEUTRAL — Kristofer C. Madu is an American private equity investor. Madu is an investor at TPG Inc., where he focuses on technology investments. He is also the founder of First Friday's Group, a technology com…
https://en.wikipedia.org/wiki/Kristofer_Madu
+ 3 more evidence sources
check_circle
Claim 6: “Copenhagen-listed shares were last seen down 7.4% while its American depositary receipts were 8.6% lower in premarket trading”
CORROBORATED
Specific figures (7.4% for Copenhagen shares and 8.6% for ADRs) are reported across multiple news-style web search results.
travel_explore
web search NEUTRAL — 2 days ago · Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a pl…
https://www.cnbc.com/2026/07/31/novo-nordisk-trial-results.h…
travel_explore
web search NEUTRAL — 2 days ago · The company reported no difference in overall mortality. Copenhagen-listed Novo Nordisk shares were last down 7.4%, while the company’s American depositary receipts fell 8.6% in premarket…
https://www.cnbctv18.com/market/novo-nordisk-shares-tumble-a…
travel_explore
web search NEUTRAL — 3 days ago · Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a pl…
https://dailyinfos24.com/2026/07/31/novo-nordisk-shares-dive…
schedule
Claim 7: “successful launch of the Wegovy pill, the first oral GLP-1 for weight loss, in the U.S. in January”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 8: “Eli Lilly launched a rival pill, Foundayo, in April”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 9: “serious infections were more common with ziltivekimab”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results regarding the frequency of serious infections in the ziltivekimab group.
info
Claim 10: “There was no difference in overall mortality”
SINGLE SOURCE
One web search result mentions 'The company reported no difference in overall mortality,' but this is not corroborated by other independent sources in the provided evidence.
schedule
Claim 11: “Over the summer, Novo launched the pill in the UAE and the U.K.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 12: “the company's Danish shares had fallen 7% year-to-date and were down about 70% from their mid-2024 peak”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
verified
Claim 13: “ziltivekimab, which blocks the inflammatory IL-6 pathway”
VERIFIED BY REFERENCE
Wikipedia explicitly states that ziltivekimab is a monoclonal antibody that targets interleukin 6 (IL-6), and other sources confirm it blocks the IL-6 inflammatory pathway.
travel_explore
web search NEUTRAL — Ziltivekimab is an investigational new drug being developed by Novo Nordisk for the treatment of various inflammatory diseases. It is a fully human monoclonal antibody that targets interleukin 6 (IL-6…
https://en.wikipedia.org/wiki/Ziltivekimab
travel_explore
web search NEUTRAL — Ziltivekimab targets IL-6, the protein that IL-1β directly induces. If blocking IL-1β reduces events by 15%, a reasonable hypothesis was that blocking its principal downstream target — thereby also re…
https://www.techtimes.com/articles/322480/20260731/ziltiveki…
travel_explore
web search NEUTRAL — The study tested whether ziltivekimab, a once-monthly injection that blocks the IL-6 inflammatory pathway, could cut the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke compa…
https://qz.com/novo-nordisk-ziltivekimab-heart-drug-trial-fa…
check_circle
Claim 14: “the company released disappointing results from a head-to-head trial of its next-generation weight-loss drug CagriSema versus Eli Lilly's rival medicine”
CORROBORATED
Three independent web search results from February 2026 confirm that CagriSema underperformed Eli Lilly's Zepbound in a head-to-head trial.
travel_explore
web search NEUTRAL — Feb 23, 2026 · Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The Phase III REDEFINE 4 trial (NCT06131437) failed to meet its pri…
https://www.clinicaltrialsarena.com/news/novo-nordisks-cagri…
travel_explore
web search NEUTRAL — Feb 23, 2026 · Novo Nordisk's next-generation obesity drug CagriSema underperformed Eli Lilly's Zepbound in a head-to-head trial, the Danish drugmaker said on Monday, as it suffered a setback in...
https://www.reuters.com/business/healthcare-pharmaceuticals/…
travel_explore
web search NEUTRAL — Feb 23, 2026 · Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, h…
https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema…
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.